Teriparatide
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
| Clinical data | |
|---|---|
| Pregnancy category |
|
| Routes of administration | SubQ |
| ATC code | |
| Pharmacokinetic data | |
| Bioavailability | 95% |
| Metabolism | Hepatic (nonspecific proteolysis) |
| Elimination half-life | SubQ: 1 hour |
| Excretion | Renal (metabolites) |
| Identifiers | |
| PubChem CID | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C181H291N55O51S2 |
| Molar mass | 4117.72 g/mol |
|
WikiDoc Resources for Teriparatide |
|
Articles |
|---|
|
Most recent articles on Teriparatide Most cited articles on Teriparatide |
|
Media |
|
Powerpoint slides on Teriparatide |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Teriparatide at Clinical Trials.gov Clinical Trials on Teriparatide at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Teriparatide
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Teriparatide Discussion groups on Teriparatide Patient Handouts on Teriparatide Directions to Hospitals Treating Teriparatide Risk calculators and risk factors for Teriparatide
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Teriparatide |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Teriparatide (Forteo®) is a recombinant form of parathyroid hormone, used in the treatment of advanced osteoporosis. It is manufactured and marketed by Eli Lilly and Company.
Administration
Teriparatide is administered by injection once a day in the thigh or abdomen. The recommended dose is 20 μg per day.
Uses
Teriparatide has recently been given to patients in an ongoing clinical trial to evaluate its effectiveness in treating the symptoms of osteogenesis imperfecta.[1]
Teriparatide should not be prescribed for patients who are at increased risks for osteosarcoma. This includes those with Paget's Disease of bone or unexplained elevations of serum alkaline phosphate, open epiphysis, or prior radiation therapy involving the skeleton.
Mechanism of action
Teriparatide is the portion of human parathyroid hormone (PTH),amino acid sequence 1 through 34 of the complete molecule which contains amino acid sequence 1 to 84. Endogenous PTH is the primary regulator of calcium and phosphate metabolism in bone and kidney. Daily injections of teriparatide stimulate new bone formation leading to increased bone mineral density.
Teriparatide is the first FDA approved agent for the treatment of osteoporosis that stimulates new bone formation.
FDA approval
Teriparatide was approved by the Food and Drug Administration (FDA) on 26 November, 2002, for the treatment of osteoporosis in men and postmenopausal women who are at high risk for having a fracture. The drug is also approved to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture.
References
External links
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Infobox drug articles without a structure image
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs
- Eli Lilly and Company
- Endocrinology